NM Developmental Therapeutics Program

The Woman's Board supported the Northwestern Medicine Developmental Therapeutics Fellowship Program with a $2 million gift initiated in 2013.

This institute, launched in 2013, is making available the latest innovations to patients in most need at Northwestern Medicine in Chicago by accelerating the timeline from discoveries in the lab to first clinical trials and training the next generation of collaborative researchers. With a new approach of personalized medicine, NMDTP seeks specific treatments for each patient based on genetic biomarkers.

On April 11, 2016, NMDTI became the Developmental Therapeutics Program of the Division of Hematology/Oncology, reflecting its optimal integration within the Division of Hematology/Oncology and the opportunities emerging as the program develops a full-spectrum, multi-disciplinary team. Dr. Devalingam Mahalingam and Dr. Young Chae are the Co-Directors of the Developmental Therapeutics Program.

NMDTI, now DTPHOD, has quickly become one of the nation's premier destinations for clinical trials and research. Due to the demand for Phase I trials and the success of the growing team, expanded clinic space is now open in the Olson Pavilion in order to better serve patients. Developmental Therapeutics is integrated with inpatient facilities and is also now serving patients at Northwestern Lake Forest Hospital.

“We’re giving cancer patients a future and creating new standards of care. Chicago now has a world–leading program and a team developing personalized treatment.”